Lamellar Biomedical Eyes Sales And Pipeline Growth With New Cash

11 May 2017

• By Catherine Longworth

Scottish biotech Lamellar Biomedical has raised new cash to support commercialization of its pipeline of biomimetic products. The company's proprietary Lamellasome technology creates mimetics that replicate the actions of lamellar bodies to target diseases and conditions associated with thick sticky mucosal surfaces.

Scottish biotech company Lamellar Biomedical has raised £5.75m ($7.5m) in a Series C round to support ongoing clinical activities and initial commercialization of its pipeline of biomimetic products targeting a range of diseases including dry eye and cystic fibrosis. This latest financing was led by existing majority shareholder Invesco and supported by the Scottish Investment Bank (SIB), the investment arm of Scottish Enterprise.

Lamellar's products are based on mimetics of native extra-alveolar lamellar bodies, which are micro-scale lipid vesicles. Under normal physiological conditions,...